Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded $11.8 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae. In January 2024, the company announced an exclusive collaboration agreement with AstraZeneca for up to three years to research potential vaccines for bacterial pathogens.
| Website | http://www.omniose.com |
| Employees | 23 (19 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Data Science, Ai-Powered Solutions, Machine Learning, Data Management, Data Analytics, Big Data Analytics, Enterprise Software, Predictive Modeling, Software Solutions, Technology Solutions, Digital Transformation, Process Automation, Business Intelligence, Decision Support, Cloud Computing, Data Visualization, It Solutions, Risk Management, Strategic Planning, Consulting Services |
| Competitors | Medidata Solutions, Veeva Systems, Oracle, Oracle Health Information, SAP, IBM, CureMetrix, Flatiron Health, Signant Health, Clinical ink +42 more (view full list) |
Looking for a particular Omniose employee's phone or email?
Timothy Cooke is the CEO of Omniose.
19 people are employed at Omniose.